StockNews.com Begins Coverage on Check-Cap (NASDAQ:CHEK)

Research analysts at StockNews.com initiated coverage on shares of Check-Cap (NASDAQ:CHEK) in a research report issued to clients and investors on Wednesday. The firm set a “sell” rating on the medical research company’s stock.

Check-Cap Stock Up 6.4 %

Check-Cap stock opened at $0.90 on Wednesday. Check-Cap has a 12-month low of $0.56 and a 12-month high of $3.45. The firm’s fifty day moving average is $1.08 and its 200 day moving average is $1.37. The company has a market capitalization of $5.26 million, a PE ratio of -0.30 and a beta of 0.16.

About Check-Cap

Check-Cap Ltd., a clinical stage medical diagnostics company, engages in the development of a capsule-based screening technology that utilizes ultra-low-dose X-rays to scan the inner lining of the colon for precancerous polyps, and other structural abnormalities in Israel. Its C-Scan system consists of C-Scan Cap, an X-ray scanning capsule for detection of suspected polyps; C-Scan Track, a disposable system attached to the patient's back through biocompatible adhesive skin patches; and C-Scan View software, a client/server-based application that enables procedure data download from the C-Scan Track, data analysis, and report generation.